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Aims Patient access to reperfusion therapy and the use of primary percutaneous coronary intervention (p-PCI) or throm-
bolysis (TL) varies considerably between European countries. The aim of this study was to obtain a realistic contem-
porary picture of how patients with ST elevation myocardial infarction (STEMI) are treated in different European
countries.
Methods
and results
The chairpersons of the national working groups/societies of interventional cardiology in European countries and
selected experts known to be involved in the national registries joined the writing group upon invitation. Data
were collected about the country and any existing national STEMI or PCI registries, about STEMI epidemiology,
and treatment in each given country and about PCI and p-PCI centres and procedures in each country. Results
from the national and/or regional registries in 30 countries were included in this analysis. The annual incidence of
hospital admission for any acute myocardial infarction (AMI) varied between 90–312/100 thousand/year, the inci-
dence of STEMI alone ranging from 44 to 142. Primary PCI was the dominant reperfusion strategy in 16 countries
and TL in 8 countries. The use of a p-PCI strategy varied between 5 and 92% (of all STEMI patients) and the use
of TL between 0 and 55%. Any reperfusion treatment (p-PCI or TL) was used in 37–93% of STEMI patients. Signiﬁ-
cantly less reperfusion therapy was used in those countries where TL was the dominant strategy. The number of
p-PCI procedures per million per year varied among countries between 20 and 970. The mean population served
by a single p-PCI centre varied between 0.3 and 7.4 million inhabitants. In those countries offering p-PCI services
to the majority of their STEMI patients, this population varied between 0.3 and 1.1 million per centre. In-hospital
mortality of all consecutive STEMI patients varied between 4.2 and 13.5%, for patients treated by TL between 3.5
and 14% and for patients treated by p-PCI between 2.7 and 8%. The time reported from symptom onset to the
ﬁrst medical contact (FMC) varied between 60 and 210 min, FMC-needle time for TL between 30 and 110 min,
and FMC-balloon time for p-PCI between 60 and 177 min.
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organized p-PCI networks was associated with fewer patients overall receiving some form of reperfusion therapy.
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Introduction
Primary percutaneous coronary intervention (PCI) and thromboly-
sis (TL) represent two alternative reperfusion strategies for ST
elevation acute myocardial infarction (STEMI). In common, TL is
considered to be more widely available and can be started faster
than primary PCI. In many randomized clinical trials,
1–6 primary
PCI has been shown to be superior to TL in reducing mortality,
re-infarction, and stroke. This beneﬁt is related to a much higher
early mechanical reperfusion rate (ca. 90%) compared with
pharmacological reperfusion rate (ca. 50%), to the ability of simul-
taneously treating the underlying stenosis and ﬁnally to the lower
risk of severe bleeding. The most recent European Society of Car-
diology (ESC) guidelines
7,8 recommend primary PCI as the pre-
ferred treatment whenever it is available within 90–120 min of
the ﬁrst medical contact (FMC). The aim of this project was to
analyse the use of reperfusion treatments across Europe at the
time when these new ESC guidelines were published.
Methods
The European Association for Percutaneous Cardiovascular Interven-
tions (EAPCI) invited the chairpersons of the national working groups/
societies of interventional cardiology in all 51 European Society of Car-
diology (ESC) countries and selected experts known to be involved in
the national registries of STEMI to join this project. Positive replies
were received from 30 countries. Data were collected about the
country and any existing national STEMI or PCI registries, about
STEMI hospital admissions and treatment in each given country, and
about PCI and primary PCI centres and procedures in each country.
Speciﬁcally, each participating national working group (or society) pro-
videdtheprecisenumberofallexistingPCIhospitalsinthegivencountry
and how many of them offer non-stop (24/7) primary PCI services.
Primary PCI centre (24/7) was deﬁned as PCI hospital not using TL
for thetreatment of STEMI patients, in other words hospital performing
primary PCI in all STEMI patients, 24 h/day and 7 days/week.
Results from 30 European countries were included in this analysis
(Tables 1 and 2). These data reﬂect the situation in years 2007–
2008 for most countries, but in 2006 or 2005 for a few, in whom
the most recent data were not available.
Those national data already published are listed in the references
section
9–27 and the names of ongoing registries and/or surveys are
listed in the appendix and more details in Table 1.
Besidesobtainingthenumbersfromtheindividualcountries,thecontri-
butorswere also askedto describe subjectively, what they considertobe
themainbarriersforbetterp-PCIimplementationandtocommentonthe
possible inﬂuence of hospital/staff reimbursement on the local situation.
Statistical analysis
Data are presented in the descriptive format as we received them
from each individual country (see appendix for the list of contributors).
The SPSS 12.0 statistical package was used to ﬁt the linear regression
lines.
Results
Annual incidence of hospital admission
for acute myocardial infarction
The annual incidence of hospital admission for any acute myocar-
dial infarction (AMI) varied between 90–312/100 000 inhabi-
tants/year and the incidence of hospital admissions for STEMI
alone between 44–142/100 000 inhabitants/year (Table 2).
Reperfusion strategy use
Primary PCI is the dominant reperfusion strategy in 16 countries
and TL in 8 countries. From ﬁve countries (Denmark, Estonia,
Lithuania, Norway, and Spain), only information about primary
PCI (and not about TL) was available. The use of a p-PCI strategy
varies between 5 and 92% (of all STEMI patients) and the use of TL
between 0 and 55%. Any reperfusion treatment (p-PCI or TL) is
used in 37–93% of STEMI patients (Figure 1). Overall, in those
countries using TL as the dominant strategy, the overall population
receiving some form of reperfusion therapy is lower (only 55%
patients are treated, although this varied considerably from
country to country).
The population need for primary
PCI services
The number of primary PCI procedures per 100 000 inhabitants
per year (Table 3; Figure 2) ranged from 2 to 97. The mean popu-
lation served by a single p-PCI centre (Table 4) varies between 0.3
and 7.4 million inhabitants. In those countries offering p-PCI ser-
vices to the majority of their STEMI patients, this population
varies between 0.3 and 1.1 million per centre. There was a weak
correlation between numbers of PCI procedures and the gross
domestic product per capita (Figure 3; Table 3).
Mortality
The in-hospital mortality of all consecutive STEMI patients
(Table 5) varies between 4.2 and 13.5%, for patients treated by
TL between 3.5 and 14%, and for patients treated by primary
PCI between 2.7 and 8%.
Time delays
The time from symptom onset to the FMC (deﬁned as the time of
diagnostic ECG) ranged from 60 to 210 min, FMC-needle time for
TL between 30 and 110 min and FMC-balloon time for p-PCI
between 60 and 177 min. These FMC-balloon times are given for
all primary PCI procedures, irrespective of whether the patient
P. Widimsky et al. 944.............................................................................................................................................................................................................................................
Table 1 National registries and other sources of the countries’ data for this study
Country Year STEMI registry (name) PCI registry (name) Other registry or survey (name) Expert
estimate only
Completeness of STEMI
capturing per period and
region
Austria 2005–07 VIENNA STEMI registry
34 Austrian Heart Catheter Registry
36 Austrian Acute PCI Registry
37 – 100% in Vienna region, ca. 50% for
Austria
Belgium 2008 Belgian STEMI registry Belgian Working Group Interventional
Cardiology registry
50%
Bulgaria 2007 National Health Insurance Fund National Health Insurance Fund, Bulgarian
WG Interventional Cardiology
– – 100%
Croatia 2005–08 Croatian Cardiac Society, WG
for Acute Coronary
Syndromes
Croatian Cardiac Society; Hospital PCI
Registries
Zagreb AMI Registry; Croatian
Institute of Public Health
90% for STEMI; 100% for PCI
Czech Republic 2005–07 CZECH registry (all ACS)
19 NRKI registry – – 100% for all ACS in the CZECH
registry
Denmark 2007 None Danish Heart Registry – For AMI not
undergoing PCI
100% for p-PCI
Estonia 2008 Estonian Myocardial Infarction
Registry, WG on Acute
Coronary Syndromes
–– – 1 0 0 %
France 2005 FAST-MI
33 FAR – – 60% of ICUs
Finland 2006 – – Registry of Cardiovascular Diseases,
National Institute for Health and
Welfare
18
– ca. 90% for all AMI
Germany 2007–08 German Myocardial infarction
registry
46
– Herzbericht 2007
47 –2 5 %
Greece 2006 HELIOS
14,16 – Hellenic Study of AMI
15 –1 0 0 %
Hungary 2004–08 National Health Insurance
Database
Registry of the Working Group of
Interventional Cardiology
PCI Network in the Middle-Hungarian
region (Budapest)
– 100% for all
Italy 2006–08 VENERE,
41 In-ACS (2007); BLITZ
3 (2008)
GISE Registry (GISE¼Italian Society of
Interventional Cardiology)
Istituto Superiore di Sanita ` (ISS) – 100% in Veneto Region; p-PCI
100% in GISE (all Italy); 80% in
BLITZ 3
Israel 2006 ACSIS – – – 100%
Latvia 2008 Latvian registry of acute coronary
syndromes
Latvian registryof acutecoronarysyndromes – – 100%
Lithuania 2007–08 – Lithuanian PCI registry – Yes for AMIs
without PCI
100% for p-PCI only
F.Y.R. Macedonia 2007–08 – Hospital based registries in all existing PCI
centres
– – 95% in Skopje, ca. 80% for
Macedonia
The Netherlands 2008 – Dutch National PCI Registry (BHN) – – –
Norway 2007 – PCI-hospital based registries – For patients not
treated by PCI
Not known (PCI data only)
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Table 1 Continued
Country Year STEMI registry (name) PCI registry (name) Other registry or survey (name) Expert
estimate only
Completeness of STEMI
capturing per period and
region
Poland 2004–07 PL-ASC Registry PCI registry of the WG on Cardiovascular
Interventions of the Polish Cardiac
Society
–1 0 0 %
Portugal 2008 National ACS Registry 2002,
43
updated 2009
44
–– – N . A .
Romania 2007–08 RO-STEMI – – – 100%
Serbia 2007 National Institute for Health Working group on interventional
cardiology
42
100%
Slovakia 2007 SLOVAKS registry Registry of the Working Group
Interventional Cardiology (Slovak Society
of Cardiology)
– – 46% of all STEMI and 100% of
p-PCI in Slovakia
Slovenia 2007 National survey National survey – – 100%
Spain 2007 – Registro Espan ˜ol de Hemodina ´mica y
Cardiologı ´a Intervencionista
45
– Yes for AMIs
without PCI
N.A.
Sweden 2007 RIKS-HIA SCAAR – – 100%
Switzerland 2007 AMIS Plus (STEMI/NSTEMI/UA
registry
48–50)
Swiss PCI survey
51 – – 100% for p-PCI, 43% for STEMIs
Turkey 2007 TUMAR registry – – Yes, partly N.A.
UK 2005–08 Myocardial Ischaemia National
Audit Project (MINAP)
38
British Cardiovascular Intervention Society
(BCIS)
39 and Central Cardiac Audit
database (CCAD)
40
– – 100%
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6underwent interhospital transfer or was directly admitted to the
PCI hospital (Table 6; Figures 4 and 5).
STEMI initial presentation
Only approximately half of the patients arrive at the hospital via an
EMS ambulance. This proportion varies considerably between
countries: from 17% (Greece) to 85% (UK) (Figure 6).
Discussion
Geographic differences, heterogenity
of care
Primary PCI appears to be now the dominant treatment of STEMI
in the majority of countries: Scandinavia (Norway, Denmark,
Sweden, and Finland), Central Europe (Czech Republic, Slovenia,
Poland, Hungary, Austria, and Croatia), West Europe (Germany,
Belgium, France, Switzerland, and the Netherlands), Italy, and
Israel. Several countries have the infrastructure available, but do
not use it sufﬁciently to treat most of their AMI patients—this
holds true especially for the South Europe (Greece, Bulgaria,
Portugal, Spain, and Turkey) and for the UK and Slovakia
(however, national programs for p-PCI implementation have
already started in these latter two countries). The described
‘North-South gradient’ in primary PCI services is typically seen
in Italy: the Northern part of Italy has p-PCI rates similar to
Central or West Europe, while the Southern part of Italy has
rates similar to Greece or Turkey. Unfortunately, no or few
data have been obtained from Ireland, Iceland, East Europe
(Belarus, Ukraina, Russia, Moldova, Bosnia i Herzegovina,
FYROM, Albania, and Georgia) and from the Mediterranean
non-European countries (ESC members).
The heterogeneity of care is known from international
registries—e.g. the GRACE registry showed that the care-seeking
...............................................................................................................................................................................
Table 2 Population data and acute myocardial infarction annual incidence
Country Country population (www.
populationmondiale.com)
Hospitalized
STEMI/year
STEMI/100
thousand/year
Hospitalized
AMI (any)
AMI/100
thousand/year
Austria 8 199 783 7800 95 16 000 195
Belgium 10 584 534 7000 66 12 000 114
Bulgaria 7 640 238 8726 114 11 285 148
Croatia 4 493 312 3600 82 N.A. N.A.
Czech Republic 10 228 744 6761 66 20 048 196
Denmark 5 468 120 N.A. N.A. N.A. N.A.
Estonia 1 315 912 1751 133 3502 266
France 62 448 977 35 000 55 65 000 105
Finland 5 300 484 4674 88 16 446 310
Germany 82 217 837 100 000 121 208 000 250
Greece 10 706 290 11 780 110 19 853 185
Hungary 9 956 108 8900 89 18 500 186
Italy 58 147 733 67 500 116 147.500 254
Israel 7 337 000 5500 75 10 000 136
Latvia 2 270 894 1437 63 N.A. N.A.
Lithuania 3 575 439 3000 84 N.A. N.A.
F.Y.R. Macedonia 2 049 613 1765 86 N.A. N.A.
The Netherlands 16 405 399 N.A. N.A. N.A. N.A.
Norway 4 703 779 3900 83 12 650 276
Poland 38 518 241 50 000 130 90 000 234
Portugal 10 642 836 11 104 104 N.A. N.A.
Romania 22 276 056 10 000 45 20 000 90
Serbia 7 400 000 6079 82 8655 117
Slovakia 5 447 522 3635 67 7635 140
Slovenia 2 009 245 1210 60 N.A. N.A.
Spain 45 116 894 40 000 89 120 000 266
Sweden 9 031 088 6000 66 21 000 232
Switzerland 7 593 494 N.A. N.A. 11 337 149
Turkey 70 586 256 100 000 142 220 000 312
UK 60 776 238 27 000 44 105 000 173
STEMI, ST elevation acute myocardial infarction; AMI, acute myocardial infarction, N.A., not available.
Reperfusion therapy for STEMI in Europe 947behaviour in patients with acute coronary disease differs among
countries or continents.
28
Annual incidence of the hospital
admissions for acute myocardial
infarction
The annual incidence of hospital admission for any AMI varied con-
siderably, as was the case for the incidence of STEMI alone. Those
countries with the most precise data (e.g. covering 100% of the
population either in the whole country or in selected regions/
counties—see Table 1) reported the incidence close to the
overall mean numbers (ca. 1900 for all AMIs and ca. 800 for
STEMIs). In other words, the annual incidence of ca. 1900 hospital
admissions for any AMI per year per million population seems to
be typical for the European population. This can be used for plan-
ning infrastructure because most of these patients will need coron-
ary angiography and subsequent PCI or CABG during their
hospital stay.
Reperfusion strategy use
It is of note that primary PCI is already today the leading reperfu-
sion strategy in most European countries. Several countries can
serve as evidence that p-PCI may be able to be offered to as
many as 70–90% of all STEMI patients in the whole country. An
increased use of primary PCI as the preferred reperfusion
therapy is identiﬁed by this data when compared with the
second Euro Heart Survey on Acute Coronary Syndromes
(EHS-ACS-II).
29 Results of our study challenge the traditional
opinion that TL is the strategy more suitable for widespread appli-
cation. In some countries, the opposite appears to be true: reper-
fusion as a whole is offered to less of the STEMI population in
those countries using TL as the dominant strategy. This may be
related to the many contraindications for thrombolytic therapy
and also to the fear of using TL in patients over 75 years of age,
who present a signiﬁcant proportion of all STEMI patients today
(e.g. 31% of all hospitalized AMI patients in the Netherlands
30).
Thus p-PCI, despite its logistic complexity, appears to offer
broader population reach in some countries.
The population need for primary PCI
services
The number of primary PCI procedures per million per year in
these countries, covering their population needs, varies between
ca. 600 and 900 per million. In these countries, one PCI centre
is serving a population of ca. 0.3–0.8 million per centre. These
numbers might serve as a reference for planning the infrastructure.
Mortality
The data on mortality between countries cannot be directly com-
pared due to the different methodology of the national registries
or surveys. The Czech Republic can serve as an example of
these methodological limitations: the in-hospital mortality after
p-PCI in the national PCI registry reported by the cardiologists
was 3.5%, while after matching the data with the national deaths
registry this number rose to 6.7%. This can be explained by the
fact that cardiologists are frequently entering the registry data
immediately after the procedure, when the patient is subsequently
moved from the interventional cardiology unit to another unit
(long-term facility, local community hospital, cardiac surgery, long-
term rehabilitation unit, etc.) and thus they do not reﬂect the true
(total) hospital outcome.
As with all registries, these data must be interpreted with great
caution. The demographic features of patients treated by p-PCI
may well be different from those treated by TL. In the National
Figure 1 Hospitalized STEMI treatment in Europe (data from national registries or surveys). 100%, all hospitalized STEMI patients in each
given country; green colour, STEMI patients treated by primary PCI; red colour, STEMI patients treated by thrombolysis; black colour,
STEMI patients not treated with any reperfusion. Countries abbreviations: CZ, Czech Republic; SLO, Slovenia; DE, Germany; CH, Switzerland;
PL, Poland; HR, Croatia; SE, Sweden; HU, Hungary; BE, Belgium; IL, Israel; IT, Italy; FIN, Finland; AT, Austria; FR, France; SK, Slovakia; LAT, Latvia;
UK, United Kingdom; BG, Bulgaria; PO, Portugal; SRB, Serbia; GR, Greece; TR, Turkey; RO, Romania.
P. Widimsky et al. 948Infact Angioplasty Project (NIAP) study in the UK, for example, the
patients treated by p-PCI were younger than those treated by TL,
suggesting a tendency to use p-PCI in ﬁtter patients who have a
lower predicted mortality regardless of treatment strategy. Con-
versely, it is also possible that some of the difference is due to
the ‘real world’ inclusion of higher risk patients, for whom the
differential beneﬁts of PCI might be greater. The highest risk
patients (elderly, cardiogenic shock, polymorbid, etc.) are usually
excluded from the randomized trials and p-PCI is certainly an
optimal treatment for this high-risk group, while TL is associated
with high mortality or high complication rates in cardiogenic
shock or elderly patients.
The lack of information about the baseline characteristics of
individual patients in our study and subsequently the inability to
statistically compensate for probable differences between the
two reperfusion groups prohibit us from making any adjusted
comparison of mortality outcome between p-PCI and TL.
However, properly analysed consecutive STEMI patients from a
whole European country (Sweden) showed that p-PCI was
superior to TL with lower 30 day and 1 year mortality.
31,32
Time delays
If 30 min (as an expected minimal time to achieve pharmacologic
reperfusion) are arbitrarily added to FMC-needle time, then TL
is only minimally faster in opening the coronary artery when com-
pared with p-PCI in our study. The importance of time delays can
be easily demonstrated on the situation in France: the time delays
in reperfused patients are short and thus the mortality is low. Fur-
thermore, the difference (125 min; Table 5) between the short
TL-related delay and the long PCI-related delay causes no signiﬁ-
cant difference in mortality between the two treatment strategies
in this country.
33 In other words, p-PCI is superior to TL only
when the time difference between these two strategies is below
2 h. We are fully aware that this survey cannot directly compare
...............................................................................................................................................................................
Table 3 Percutaneous coronary interventions (PCI) perone million inhabitants compared with gross domestic product
(GDP) per capital (in US dollars, according to the UN statistics for 2007, http://unstats.un.org/unsd/demographic/
products/socind/inc-eco.htm)
Country All PCIs/year All PCIs/million Primary PCIs/year (% of all PCIs) Primary PCIs/million GDP per capita (US$)
Austria 19 342 2358 3500 (18%) 426 44 652
Belgium 22 000 2079 3300 (15%) 312 43 469
Bulgaria 6000 785 1801 (30%) 236 5177
Croatia 4000 890 1150 (22%) 255 11 256
Czech Republic 21 531 2105 6720 (31%) 657 16 880
Denmark 10 500 1920 2691 (26%) 481 57 256
Estonia 2471 1878 485 (20%) 369 15 932
France 120 000 1921 14 400 (12%) 231 40 089
Finland 8894 1678 826 (9%) 156 46 370
Germany 299 600 3660 60 000 (20%) 730 40 162
Greece 19 311 1804 1022 (5%) 95 28 111
Hungary 18 500 1858 5700 (31%) 573 13 777
Italy 128 428 2161 22 421 (17%) 376 35 585
Israel 20 000 2726 3500 (17%) 477 23 382
Latvia 5956 2624 410 (7%) 181 11 930
Lithuania 4143 1159 1485 (36%) 415 11 307
F.Y.R. Macedonia 2516 1227 981 (39%) 478 3703
The Netherlands 36 367 2217 11 201 (31%) 683 46 669
Norway 11 890 2530 2632 (22%) 560 82 464
Poland 75 024 1948 26 457 (35%) 687 11 007
Portugal 9873 919 1902 (19%) 179 20 990
Romania 6560 294 450 (7%) 20 7523
Serbia 6395 864 1161 (18%) 157 5382
Slovakia 5730 1061 1924 (34%) 356 13 701
Slovenia 3336 1661 1043 (31%) 519 22 936
Spain 60 457 1340 11 322 (19%) 251 32 450
Sweden 19 000 2103 5421 (29%) 600 49 873
Switzerland 36 817 4849 7363 (20%) 970 56 578
Turkey 70 000 991 5500 (8%) 78 6511
UK 77 373 1273 8153 (11%) 134 45 549
Reperfusion therapy for STEMI in Europe 949TL and p-PCI. Both treatments can certainly be offered more
expeditiously than was shown in this study. This should be one
of the main goals for future improvements.
Primary PCI volume per centre
and per operator
Primary PCI volume per centre and per operator may inﬂuence the
outcomes, especially of STEMI patients, where the complexity of
care is more important compared with elective PCI. Unfortunately,
this study was not designed to collect such data. The experience
from countries, using primary PCI for vast majority of their
STEMI patients, shows that a population between 0.3 and 1.1
million per one primary PCI (i.e. non-stop, 24/7) centre results
in ca. 200–800 primary PCI procedures/year/centre. This may be
considered optimal. Population per centre ,0.3 million results in
low numbers of STEMI and thus the experience of the team may
not be sufﬁcient. A population signiﬁcantly greater than one
million results in ‘overload’ of the centre by too many infarcts
(of course only if all infarcts from that region are admitted to
this centre). The PCI volume per operator is probably less impor-
tant than PCI volume per centre, as there are very few low volume
operators in the high volume centres. The optimal case load may
be anywhere between 50–100 primary PCIs/operator/year.
Reimbursement
In most European countries (Austria, Croatia, Czech Republic,
Denmark, Germany, Greece, Hungary, Italy, Israel, Lithuania, the
Netherlands, Norway, Poland, Portugal, Serbia, Slovakia, Slovenia,
Sweden, and Switzerland), the reimbursement systems supports
primary PCI—i.e. the PCI hospital is reimbursed adequately, the
non-PCI hospital in general does not lose money by sending
patients for primary PCI and Emergency Medical Services (EMS)
transfers are reimbursed. In some countries, PCI centres
receive reimbursement for primary PCIs, but the small hospitals
lose money when STEMI patients are admitted initially to PCI
centres (Belgium, Bulgaria, Spain, Turkey, and UK) or interhospital
transfer is not appropriately reimbursed (Belgium and Bulgaria). In
only one country (Romania), PCIs (any) are not adequately reim-
bursed in general (low limits on numbers of centres and
procedures).
Barriers for the implementation
of primary PCI in Europe
Reimbursement is only rarely a real problem (see above). EMS
interhospital transport is not supported by adequate reimburse-
ment in some countries, and in smaller districts only a single
EMS ambulance is in service during the off-hours and cannot go
Figure 2 Primary PCIs per year per million inhabitants in European countries. Grey colour, no data available; blue colour, countries parti-
cipating in this study.
P. Widimsky et al. 950outside this district. Low stafﬁng levels (lack of interventional car-
diologists and/or nurses and other support staff) prevent many
smaller PCI hospitals running a non-stop (24/7) primary PCI ser-
vices. A conservative attitude of internists and even some noninva-
sive cardiologists, who still prefer to use TL instead of sending their
patients to other cardiologists, is the most frequently quoted
barrier, along with the insufﬁcient motivation of interventional car-
diologists and/or nurses to run the non-stop (24/7) services even
when the stafﬁng is sufﬁcient (they are often not paid adequately
for this activity). The use of helicopters for short distance transfers
actually prolongs the delays and should in general be avoided; heli-
copter transfer is extremely useful for patients with long distance
transfers but is expensive. In several countries (Austria, Croatia,
Czech Republic, Norway, and Sweden), the good cooperation
between the national society of cardiology, government, and
insurance companies (health care funds) signiﬁcantly contributed
to the development of p-PCI services.
This survey suggests that medical and non-medical staff are the
main barriers for wider p-PCI implementation: with reasons
ranging from low stafﬁng levels (lack of interventional cardiologists
and/or nurses and other staff groups) through to the conservative
attitude of many physicians and to the insufﬁcient motivation of
interventional cardiologists and/or nurses to run demanding
non-stop (24/7) services. In some countries, the lack of a systema-
tic training program has resulted in a lack of interventional cardi-
ologists and foreign cardiologists have been invited to work there
in order to ﬁll this gap. An inappropriate reimbursement system is
the limitation of p-PCI only in a few countries. Some of these
problems might be overcome by organizing cooperating networks
of PCI hospitals in close vicinity and organized by the local
..............................................................................................................................................................................
Table 4 Numbers of PCI centres and population per one centre
Country All PCI
centres
Population
per any
PCI centre
Primary
PCI centres
(non-stop,
24/7)
Population
per primary
PCI centre
(24/7)
Austria 34 282 751 24 341 000
Belgium 36 294 015 30 352 817
Bulgaria 21 363 820 9 850 000
Croatia 10 449 331 8 561 664
Czech Republic 22 464 943 22 464 943
Denmark 7 781 160 5 1 093 624
Estonia 3 438 637 2 657 956
France 210 297 376 200 312 245
Finland 24 220 853 2 2 650 242
Germany 430 190 000 310 265 000
Greece 40 267 657 10 1 071 000
Hungary 16 622 257 13 765 854
Italy 242 240 270 164 354 559
Israel 22 333 500 16 458 563
Latvia 5 454 179 1 2 270 894
Lithuania 6 595 906 3 1 191 813
F.Y.R.Macedonia 3 683 204 3 683 204
The Netherlands 22 745 700 22 745 700
Norway 8 587 500 6 783 963
Poland 95 405 455 74 520 516
Portugal 19 560 158 9 1 182 555
Romania 12 1 856 338 0 N.A.
Serbia 9 822 222 1 7 400 000
Slovakia 6 916 666 4 1 375 000
Slovenia 5 401 849 2 1 004 745
Spain 129 349 743 56 805 658
Sweden 29 311 417 13 694 699
Switzerland 27 281 240 20 379 675
Turkey 157 449 592 35 2 016 742
UK 98 620 165 23 2 642 445
Primary PCI centre (24/7) was deﬁned as PCI hospital not using thrombolysis for the treatment of STEMI patients, in other words hospital performing primary PCI in all STEMI
patients, 24 h/day and 7 days/week.
Reperfusion therapy for STEMI in Europe 951Figure 3 Correlation between the annual number of PCI procedures per million population and the gross domestic product per capita in
European countries. (A) All PCI procedures. (B) Primary PCI procedures.
P. Widimsky et al. 952ambulance system (EMS) as shown from the VIENNA STEMI
network.
34 The formation of local networks might help to reach
the goal.
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Limitations of this analysis
While data from 30 countries were included in this analysis, the
number of centres that participated in some of the national
registries or surveys may not be representative of the countries’
total populations. In addition, data were not gathered during the
same period of time (data from countries are based on 2005,
2006, or 2007 registries or surveys depending on what was avail-
able in each country at the time of this manuscript preparation).
Furthermore, different inclusion criteria to national registries and
surveys may lead to selection bias in the patient population. This
manuscript cannot objectively compare p-PCI vs. TL. It is poss-
ible that hospitals using primary PCI have better resource allo-
cation and organization that allows for better overall
management of all aspects of AMI, e.g. stafﬁng of these centres
may play an important role. Furthermore, we did not have indi-
vidual patient level data and it may well be that the patients
treated by p-PCI and TL are not matched (e.g. p-PCI patients
might be younger than the lytic cohort) and thus caution is
needed in making such non-randomized comparisons. The pre-
sented data are unvalidated, derived from national registries or
surveys that might not have identiﬁed all patients with AMI or
STEMI. The various registries used here differ from each other
in their methodology, this being the major limitation that led
us to the decision not to use sophisticated statistics in this
manuscript.
Due to the facts that this is a retrospective analysis of multiple
national registries, there is a lack of rigour in deﬁning the same
entry criteria to these variable registries. Furthermore, the data
about all hospital admissions (including non-PCI hospitals) were
available only from 16 countries. In the remaining 13 countries,
data were limited mostly to PCI centres (plus partial information
about admissions to non-PCI hospitals).
...............................................................................................................................................................................
Table 5 In-hospital mortality (in %) of acute myocardial infarction
Country All STEMIs STEMIs treated by
primary PCI
STEMIs treated by
thrombolysis
All AMIs (STEMI1
non-STEMI)
Austria 12 5 8 N.A.
Belgium 6.6 5.1 7 N.A.
Bulgaria N.A. N.A. N.A. N.A.
Croatia 10 5 7 N.A.
Czech Republic 8.6 6.7 N.A. 6.3
Denmark N.A. N.A. N.A. N.A.
Estonia N.A. N.A. N.A. N.A.
France 6.6 5.0 4.3 5.4
Finland 11.9 N.A. N.A. 11.8
Germany 6.8 5.3 7.8 6.1
Greece 8.9 3.6 5.1 7.7
Hungary 9.1 5.7 13 13.5
Italy 13.5 3.1 3.5 11.1
Israel 4.2 N.A. N.A. 2.8
Latvia 11.7 2.3 10.1 10.9
Lithuania N.A. 6 N.A. N.A.
F.Y.R.Macedonia N.A. 4 7 N.A.
The Netherlands N.A. N.A. N.A. N.A.
Norway N.A. 3.5 N.A. 8.5
Poland 8.5 4.2 12 7.5
Portugal 7.8 N.A. N.A. 6.0
Romania 13 7 8.5 N.A.
Serbia 9.9 3.3 9.3 10.7
Slovakia 9.4 3.2 11.1 N.A.
Slovenia N.A. 6.2 N.A. N.A.
Spain N.A. 4 N.A. N.A.
Sweden 6.2 3.8 8.8 5.2
Switzerland 6.2 3.6 4.5 5.0
Turkey 11 8 14 14
UK 9 3.7 7.3 8.7
Reperfusion therapy for STEMI in Europe 953However, despite these limitations, we believe that these data
are the best available and have clear clinical relevance.
Conclusions
The annual incidence of hospital admission for AMI in Europe is
circa 1900 patients per million population with an incidence of
STEMI of about 800 per million. A nationwide primary PCI strategy
for STEMI results in more patients being offered reperfusion
therapy. North, West, and Central Europe have already well-
developed primary PCI services, offering primary PCI treatment
to 60–90% of all STEMI patients. South Europe and the Balkans
are still predominantly using TL—associated with this is a higher
proportion of patients left without reperfusion treatment.
Countries performing annually .600 primary PCIs per million
population and having a mean population per one p-PCI centre
,750 000 are able to meet the needs of all their STEMI patients.
Countries in which (nearly) all existing PCI centres offer 24/7
p-PCI services appear to exhibit the best results. Overall, there
Figure 4 Time delays in patients treated by thrombolysis:
‘symptom onset—ﬁrst medical contact’ and ‘ﬁrst medical
contact—start of thrombolysis’ time.
Figure 5 Time delays in patients treated by p-PCI: ‘symptom
onset—ﬁrst medical contact’ and ‘ﬁrst medical contact—
balloon’ time.
................................................................................
Table 6 Median time delays (in min) in reperfusion
therapy
Country Symptoms
onset: ﬁrst
medical contact
(FMC) time
FMC-
thrombolysis
(needle)
time
FMC-
primary
PCI
(balloon)
time
Austria 90 30 115
Belgium 180 30 60
Bulgaria N.A. N.A. N.A.
Croatia 140 N.A. 120
Czech Republic 150 N.A. 120
Denmark N.A. N.A. N.A.
Estonia N.A. N.A. N.A.
France 68 57 170
Finland N.A. N.A. N.A.
Germany 100 45 120
Greece 180 N.A. 95
Hungary 210 110 115
Italy 117 30 88
Israel 90 73 92
Latvia N.A. N.A. N.A.
Lithuania 60 N.A. 120
F.Y.R.Macedonia 147 N.A. 154
The Netherlands N.A. N.A. N.A.
Norway N.A. N.A. N.A.
Poland 118 N.A. 124
Portugal N.A. 60 86
Romania 176 42 N.A.
Serbia 60 N.A. 177
Slovakia 175 65 110
Slovenia 97 N.A. 134
Spain 118 45 97
Sweden 120 40 69
Switzerland 90 94 135
Turkey N.A. N.A. N.A.
UK 68 55 118
In some countries, the FMC time is not reported and instead, the door-needle or
door-balloon times are in the table.
P. Widimsky et al. 954is a substantial heterogenity of practice in Europe and there are
many opportunities to improve the care.
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Appendix
Appendix: the full list
of contributors
Austria (VIENNA STEMI Registry, Austrian Acute PCI Registry,
Austrian Heart Catheter Registry, and Death Statistics Austria):
K.H., F.W.
Belgium (Belgian STEMI registry, Belgian Working Group Inter-
ventional Cardiology registry): M.C., Victor Legrand.
Bulgaria: S.D., Vasil Velchev.
Croatia (Croatian Cardiac Society, WG for Acute Coronary
Syndromes, Hospital PCI registries, Zagreb Registry of Acute Myo-
cardial Infarction, Croatian Institute for Public Health): D.M., Vjeran
Nikolic ´ Heiztler, Zdravko Babic ´, Mijo Bergovec, Vlasta Hrabak
Z ˇerjavic ´, Verica Kralj.
Czech Republic (CZECH registry, National PCI registry—
NRKI): P.W., P.K., Michael Zelizko, Michael Aschermann, Petr
Jansky, Frantisek Tousek, Frantisek Holm.
Denmark: S.D.K., Anders Junker.
Estonia: Toomas Marandi.
Finland: J.H.
France: J.F., N.D., Martine Gilard, Didier Blanchard.
Germany (Deutsches Herzinfarkt-Register, Herzbericht 2007):
U.Z., Volker Schaechinger, Anselm Gitt, Michael Boehm.
Greece (HELIOS registry, Hellenic Heart PCI registry): G.A.,
Georgios Papaioannou.
Hungary (Database of the National Health Insurance Fund,
National primary PCI registry): B.M., David Becker.
Israel (ACSIS registry): Alexander Battler, Basil Lewis, Shlomo
Behar.
Italy (SICI GISE PCI registry, LOMBARDIMA registry, BLITZ 3
survey, IN-ACS Outcome registry, Italian National Health
Service, Veneto region registry, Ministero del Lavoro, Salute e Poli-
tiche Sociali, Istituto Superiore di Sanita `): S.S., M.T.
Latvia (Latvian registry of ACS): Andrejs Erglis.
Lithuania: Ramunas Navickas.
F.Y.R. Macedonia: M.K.
The Netherlands: Karel T. Koch, Willem J. ter Burg.
Norway: L.A.
Poland (PL-ACS Registry, WG on Cardiovascular Interventions
registry): G.O., A.W., Lech Polonski.
Portugal: J.M.
Romania (RO-STEMI registry): Dan Deleanu, Gabriel
Tatu-Chitoiu.
Figure 6 Percentage of STEMI patients arriving to the ﬁrst hospital via EMS services. In the UK, Norway, Switzerland, and Sweden, physicians
are only in ambulance helicopters, paramedics are in ambulance cars. In all other countries, physicians are in most or all EMS ambulances (cars
and helicopters).
Reperfusion therapy for STEMI in Europe 955Serbia (National ACS registry): M.O., Z.V.
Slovakia (SLOVAKS registry): M.S., Anna Bara ´kova ´, Peter Hlava,
Ja ´n Murı ´n, Gabriel Kamensky ´, Gabriela Kaliska ´.
Slovenia (National survey 2007, Ljubljana registry): M.N.
Spain: J.A.B., A.B., J.M.F., Agustin Albarrang, Felipe Hernandez.
Sweden (RIKS-HIA/Swedeheart registry): U.S.
Switzerland (Swiss PCI registry, AMIS Plus registry): P.E., D.R.,
Stephan Windecker, Eric Eeckhout.
Turkey (TUMAR registry): Omer Kozan, Rasim Enar.
UK (MINAP registry, BCIS registry): M.B., P.L., John Birkhead.
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Nikolaus Marx, Professor of Medicine/Cardiology and
Head of Internal Medicine I, Aachen University,
Germany
Nikolaus Marx, born in 1968, was appointed to the above position in 2009. He received his medical
training at the Universities of Mainz, Geneva (Switzerland) and Du ¨sseldorf, obtaining his MD in 1994.
His thesis on growth regulation in human renal cancer cell lines was completed at the laboratory of
Prof. Gerharz at the Institute of Pathology, Mainz University. After a post-doctoral Fellowship with
Dr Peter Libby and Dr Jorge Plutzky at Brigham and Women’s Hospital, Harvard Medical School,
Marx later became a board-certiﬁed internist, then cardiologist, before specializing in intensive
care medicine in internal medicine at the University of Ulm.
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